BIOCHEMICAL PHARMACOLOGY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2191663, encodeId=0ee92191663fa, content=有没有接收了的大佬，想问一下接收了多久之后会有DOI号呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10569161455, createdName=ms4000000526230130, createdTime=Thu Mar 07 09:43:33 CST 2024, time=2024-03-07, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2181913, encodeId=94cb2181913f9, content=偏重的研究方向：抗肿瘤药物 经验分享：投稿一个月，状态一直是with editor？还是同一个editor，之前拒稿让修改后重投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fb55313293, createdName=hongzhongshi, createdTime=Tue Jan 16 07:14:44 CST 2024, time=2024-01-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2181993, encodeId=a44d21819936e, content=投稿后第四天变成了DIP，目前一周多了，发邮件给编辑也没反应，要拒也给我个准信呀。科研人时间上的无奈呀。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06d55411127, createdName=ms5000001598335110, createdTime=Tue Jan 16 15:58:49 CST 2024, time=2024-01-16, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2185972, encodeId=3dba21859e250, content=投稿界面显示：Biochemical Pharmacology is currently receiving a high number of submissions. Handling time for your manuscript may be longer than usual.确实速度慢了好多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13159126824, createdName=ms7000001842576921, createdTime=Mon Feb 05 11:22:48 CST 2024, time=2024-02-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2184772, encodeId=564b2184e7214, content=提交两个月，Under Review 了一个多月，也看到编辑邀请了9个审稿人，但都没有接受，上一次同行审稿时间是12月27日，到现在一直没有变化，发了邮件也没有收到回复，这是不想要但是一直拖着没有拒稿吗，救命一整个大焦虑，大家有这种情况吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bcf6449852, createdName=ms2000000381066259, createdTime=Tue Jan 30 09:59:08 CST 2024, time=2024-01-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2184596, encodeId=77ad218459636, content=偏重的研究方向：肿瘤;中药 经验分享：想问一下大家最近的速度快吗？两周了都还是with editor。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9c98851241, createdName=ms9000000665899893, createdTime=Mon Jan 29 10:58:34 CST 2024, time=2024-01-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2184176, encodeId=ff5421841e6a8, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肝脏药理 经验分享：1.16晚上投稿，submiteed一周，1.23with editor，1.26under review，感觉最近进度是有点慢的，不如官网宣传的3天，共大家参考。前期投稿分享：一投的pharmcological research，当天桌拒，建议转投biomedicine&pharmcptherapy，这个杂志之前预警过（不太理解），没投了。二投的中国药理学报（APS），当天桌拒，然后投了这个杂志，希望顺利吧！也祝大家的paper能顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e446571671, createdName=ms4000000706495698, createdTime=Fri Jan 26 22:32:25 CST 2024, time=2024-01-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2184603, encodeId=582f218460333, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：抗肿瘤药物;肿瘤药理 经验分享：想问一下最近大家进展快吗？两周了还在with editor , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10569161455, createdName=ms4000000526230130, createdTime=Mon Jan 29 11:06:59 CST 2024, time=2024-01-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2182052, encodeId=b715218205245, content=偏重的研究方向：神经药物 经验分享：现在投稿后 with editor 时间会很久吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae325512706, createdName=ms3000002011952066, createdTime=Tue Jan 16 20:22:30 CST 2024, time=2024-01-16, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2183494, encodeId=13e621834949b, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：黏附分子;胃癌 经验分享：已经外审12周了，窒息了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11f06507596, createdName=ms9000001327347856, createdTime=Tue Jan 23 20:06:15 CST 2024, time=2024-01-23, status=1, ipAttribution=上海)]

2024-03-07 ms4000000526230130 来自重庆

有没有接收了的大佬，想问一下接收了多久之后会有DOI号呀

11 0

[GetPortalCommentsPageByObjectIdResponse(id=2191663, encodeId=0ee92191663fa, content=有没有接收了的大佬，想问一下接收了多久之后会有DOI号呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10569161455, createdName=ms4000000526230130, createdTime=Thu Mar 07 09:43:33 CST 2024, time=2024-03-07, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2181913, encodeId=94cb2181913f9, content=偏重的研究方向：抗肿瘤药物 经验分享：投稿一个月，状态一直是with editor？还是同一个editor，之前拒稿让修改后重投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fb55313293, createdName=hongzhongshi, createdTime=Tue Jan 16 07:14:44 CST 2024, time=2024-01-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2181993, encodeId=a44d21819936e, content=投稿后第四天变成了DIP，目前一周多了，发邮件给编辑也没反应，要拒也给我个准信呀。科研人时间上的无奈呀。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06d55411127, createdName=ms5000001598335110, createdTime=Tue Jan 16 15:58:49 CST 2024, time=2024-01-16, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2185972, encodeId=3dba21859e250, content=投稿界面显示：Biochemical Pharmacology is currently receiving a high number of submissions. Handling time for your manuscript may be longer than usual.确实速度慢了好多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13159126824, createdName=ms7000001842576921, createdTime=Mon Feb 05 11:22:48 CST 2024, time=2024-02-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2184772, encodeId=564b2184e7214, content=提交两个月，Under Review 了一个多月，也看到编辑邀请了9个审稿人，但都没有接受，上一次同行审稿时间是12月27日，到现在一直没有变化，发了邮件也没有收到回复，这是不想要但是一直拖着没有拒稿吗，救命一整个大焦虑，大家有这种情况吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bcf6449852, createdName=ms2000000381066259, createdTime=Tue Jan 30 09:59:08 CST 2024, time=2024-01-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2184596, encodeId=77ad218459636, content=偏重的研究方向：肿瘤;中药 经验分享：想问一下大家最近的速度快吗？两周了都还是with editor。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9c98851241, createdName=ms9000000665899893, createdTime=Mon Jan 29 10:58:34 CST 2024, time=2024-01-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2184176, encodeId=ff5421841e6a8, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肝脏药理 经验分享：1.16晚上投稿，submiteed一周，1.23with editor，1.26under review，感觉最近进度是有点慢的，不如官网宣传的3天，共大家参考。前期投稿分享：一投的pharmcological research，当天桌拒，建议转投biomedicine&pharmcptherapy，这个杂志之前预警过（不太理解），没投了。二投的中国药理学报（APS），当天桌拒，然后投了这个杂志，希望顺利吧！也祝大家的paper能顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e446571671, createdName=ms4000000706495698, createdTime=Fri Jan 26 22:32:25 CST 2024, time=2024-01-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2184603, encodeId=582f218460333, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：抗肿瘤药物;肿瘤药理 经验分享：想问一下最近大家进展快吗？两周了还在with editor , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10569161455, createdName=ms4000000526230130, createdTime=Mon Jan 29 11:06:59 CST 2024, time=2024-01-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2182052, encodeId=b715218205245, content=偏重的研究方向：神经药物 经验分享：现在投稿后 with editor 时间会很久吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae325512706, createdName=ms3000002011952066, createdTime=Tue Jan 16 20:22:30 CST 2024, time=2024-01-16, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2183494, encodeId=13e621834949b, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：黏附分子;胃癌 经验分享：已经外审12周了，窒息了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11f06507596, createdName=ms9000001327347856, createdTime=Tue Jan 23 20:06:15 CST 2024, time=2024-01-23, status=1, ipAttribution=上海)]

2024-01-16 hongzhongshi 来自福建省

偏重的研究方向：抗肿瘤药物
经验分享：投稿一个月，状态一直是with editor？还是同一个editor，之前拒稿让修改后重投。

19 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2191663, encodeId=0ee92191663fa, content=有没有接收了的大佬，想问一下接收了多久之后会有DOI号呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10569161455, createdName=ms4000000526230130, createdTime=Thu Mar 07 09:43:33 CST 2024, time=2024-03-07, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2181913, encodeId=94cb2181913f9, content=偏重的研究方向：抗肿瘤药物 经验分享：投稿一个月，状态一直是with editor？还是同一个editor，之前拒稿让修改后重投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fb55313293, createdName=hongzhongshi, createdTime=Tue Jan 16 07:14:44 CST 2024, time=2024-01-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2181993, encodeId=a44d21819936e, content=投稿后第四天变成了DIP，目前一周多了，发邮件给编辑也没反应，要拒也给我个准信呀。科研人时间上的无奈呀。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06d55411127, createdName=ms5000001598335110, createdTime=Tue Jan 16 15:58:49 CST 2024, time=2024-01-16, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2185972, encodeId=3dba21859e250, content=投稿界面显示：Biochemical Pharmacology is currently receiving a high number of submissions. Handling time for your manuscript may be longer than usual.确实速度慢了好多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13159126824, createdName=ms7000001842576921, createdTime=Mon Feb 05 11:22:48 CST 2024, time=2024-02-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2184772, encodeId=564b2184e7214, content=提交两个月，Under Review 了一个多月，也看到编辑邀请了9个审稿人，但都没有接受，上一次同行审稿时间是12月27日，到现在一直没有变化，发了邮件也没有收到回复，这是不想要但是一直拖着没有拒稿吗，救命一整个大焦虑，大家有这种情况吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bcf6449852, createdName=ms2000000381066259, createdTime=Tue Jan 30 09:59:08 CST 2024, time=2024-01-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2184596, encodeId=77ad218459636, content=偏重的研究方向：肿瘤;中药 经验分享：想问一下大家最近的速度快吗？两周了都还是with editor。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9c98851241, createdName=ms9000000665899893, createdTime=Mon Jan 29 10:58:34 CST 2024, time=2024-01-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2184176, encodeId=ff5421841e6a8, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肝脏药理 经验分享：1.16晚上投稿，submiteed一周，1.23with editor，1.26under review，感觉最近进度是有点慢的，不如官网宣传的3天，共大家参考。前期投稿分享：一投的pharmcological research，当天桌拒，建议转投biomedicine&pharmcptherapy，这个杂志之前预警过（不太理解），没投了。二投的中国药理学报（APS），当天桌拒，然后投了这个杂志，希望顺利吧！也祝大家的paper能顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e446571671, createdName=ms4000000706495698, createdTime=Fri Jan 26 22:32:25 CST 2024, time=2024-01-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2184603, encodeId=582f218460333, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：抗肿瘤药物;肿瘤药理 经验分享：想问一下最近大家进展快吗？两周了还在with editor , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10569161455, createdName=ms4000000526230130, createdTime=Mon Jan 29 11:06:59 CST 2024, time=2024-01-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2182052, encodeId=b715218205245, content=偏重的研究方向：神经药物 经验分享：现在投稿后 with editor 时间会很久吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae325512706, createdName=ms3000002011952066, createdTime=Tue Jan 16 20:22:30 CST 2024, time=2024-01-16, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2183494, encodeId=13e621834949b, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：黏附分子;胃癌 经验分享：已经外审12周了，窒息了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11f06507596, createdName=ms9000001327347856, createdTime=Tue Jan 23 20:06:15 CST 2024, time=2024-01-23, status=1, ipAttribution=上海)]

2024-01-16 ms5000001598335110 来自湖南省

投稿后第四天变成了DIP，目前一周多了，发邮件给编辑也没反应，要拒也给我个准信呀。科研人时间上的无奈呀。

15 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2191663, encodeId=0ee92191663fa, content=有没有接收了的大佬，想问一下接收了多久之后会有DOI号呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10569161455, createdName=ms4000000526230130, createdTime=Thu Mar 07 09:43:33 CST 2024, time=2024-03-07, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2181913, encodeId=94cb2181913f9, content=偏重的研究方向：抗肿瘤药物 经验分享：投稿一个月，状态一直是with editor？还是同一个editor，之前拒稿让修改后重投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fb55313293, createdName=hongzhongshi, createdTime=Tue Jan 16 07:14:44 CST 2024, time=2024-01-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2181993, encodeId=a44d21819936e, content=投稿后第四天变成了DIP，目前一周多了，发邮件给编辑也没反应，要拒也给我个准信呀。科研人时间上的无奈呀。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06d55411127, createdName=ms5000001598335110, createdTime=Tue Jan 16 15:58:49 CST 2024, time=2024-01-16, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2185972, encodeId=3dba21859e250, content=投稿界面显示：Biochemical Pharmacology is currently receiving a high number of submissions. Handling time for your manuscript may be longer than usual.确实速度慢了好多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13159126824, createdName=ms7000001842576921, createdTime=Mon Feb 05 11:22:48 CST 2024, time=2024-02-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2184772, encodeId=564b2184e7214, content=提交两个月，Under Review 了一个多月，也看到编辑邀请了9个审稿人，但都没有接受，上一次同行审稿时间是12月27日，到现在一直没有变化，发了邮件也没有收到回复，这是不想要但是一直拖着没有拒稿吗，救命一整个大焦虑，大家有这种情况吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bcf6449852, createdName=ms2000000381066259, createdTime=Tue Jan 30 09:59:08 CST 2024, time=2024-01-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2184596, encodeId=77ad218459636, content=偏重的研究方向：肿瘤;中药 经验分享：想问一下大家最近的速度快吗？两周了都还是with editor。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9c98851241, createdName=ms9000000665899893, createdTime=Mon Jan 29 10:58:34 CST 2024, time=2024-01-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2184176, encodeId=ff5421841e6a8, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肝脏药理 经验分享：1.16晚上投稿，submiteed一周，1.23with editor，1.26under review，感觉最近进度是有点慢的，不如官网宣传的3天，共大家参考。前期投稿分享：一投的pharmcological research，当天桌拒，建议转投biomedicine&pharmcptherapy，这个杂志之前预警过（不太理解），没投了。二投的中国药理学报（APS），当天桌拒，然后投了这个杂志，希望顺利吧！也祝大家的paper能顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e446571671, createdName=ms4000000706495698, createdTime=Fri Jan 26 22:32:25 CST 2024, time=2024-01-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2184603, encodeId=582f218460333, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：抗肿瘤药物;肿瘤药理 经验分享：想问一下最近大家进展快吗？两周了还在with editor , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10569161455, createdName=ms4000000526230130, createdTime=Mon Jan 29 11:06:59 CST 2024, time=2024-01-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2182052, encodeId=b715218205245, content=偏重的研究方向：神经药物 经验分享：现在投稿后 with editor 时间会很久吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae325512706, createdName=ms3000002011952066, createdTime=Tue Jan 16 20:22:30 CST 2024, time=2024-01-16, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2183494, encodeId=13e621834949b, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：黏附分子;胃癌 经验分享：已经外审12周了，窒息了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11f06507596, createdName=ms9000001327347856, createdTime=Tue Jan 23 20:06:15 CST 2024, time=2024-01-23, status=1, ipAttribution=上海)]

2024-02-05 ms7000001842576921 来自上海

投稿界面显示：Biochemical Pharmacology is currently receiving a high number of submissions. Handling time for your manuscript may be longer than usual.确实速度慢了好多

14 0

[GetPortalCommentsPageByObjectIdResponse(id=2191663, encodeId=0ee92191663fa, content=有没有接收了的大佬，想问一下接收了多久之后会有DOI号呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10569161455, createdName=ms4000000526230130, createdTime=Thu Mar 07 09:43:33 CST 2024, time=2024-03-07, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2181913, encodeId=94cb2181913f9, content=偏重的研究方向：抗肿瘤药物 经验分享：投稿一个月，状态一直是with editor？还是同一个editor，之前拒稿让修改后重投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fb55313293, createdName=hongzhongshi, createdTime=Tue Jan 16 07:14:44 CST 2024, time=2024-01-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2181993, encodeId=a44d21819936e, content=投稿后第四天变成了DIP，目前一周多了，发邮件给编辑也没反应，要拒也给我个准信呀。科研人时间上的无奈呀。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06d55411127, createdName=ms5000001598335110, createdTime=Tue Jan 16 15:58:49 CST 2024, time=2024-01-16, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2185972, encodeId=3dba21859e250, content=投稿界面显示：Biochemical Pharmacology is currently receiving a high number of submissions. Handling time for your manuscript may be longer than usual.确实速度慢了好多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13159126824, createdName=ms7000001842576921, createdTime=Mon Feb 05 11:22:48 CST 2024, time=2024-02-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2184772, encodeId=564b2184e7214, content=提交两个月，Under Review 了一个多月，也看到编辑邀请了9个审稿人，但都没有接受，上一次同行审稿时间是12月27日，到现在一直没有变化，发了邮件也没有收到回复，这是不想要但是一直拖着没有拒稿吗，救命一整个大焦虑，大家有这种情况吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bcf6449852, createdName=ms2000000381066259, createdTime=Tue Jan 30 09:59:08 CST 2024, time=2024-01-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2184596, encodeId=77ad218459636, content=偏重的研究方向：肿瘤;中药 经验分享：想问一下大家最近的速度快吗？两周了都还是with editor。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9c98851241, createdName=ms9000000665899893, createdTime=Mon Jan 29 10:58:34 CST 2024, time=2024-01-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2184176, encodeId=ff5421841e6a8, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肝脏药理 经验分享：1.16晚上投稿，submiteed一周，1.23with editor，1.26under review，感觉最近进度是有点慢的，不如官网宣传的3天，共大家参考。前期投稿分享：一投的pharmcological research，当天桌拒，建议转投biomedicine&pharmcptherapy，这个杂志之前预警过（不太理解），没投了。二投的中国药理学报（APS），当天桌拒，然后投了这个杂志，希望顺利吧！也祝大家的paper能顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e446571671, createdName=ms4000000706495698, createdTime=Fri Jan 26 22:32:25 CST 2024, time=2024-01-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2184603, encodeId=582f218460333, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：抗肿瘤药物;肿瘤药理 经验分享：想问一下最近大家进展快吗？两周了还在with editor , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10569161455, createdName=ms4000000526230130, createdTime=Mon Jan 29 11:06:59 CST 2024, time=2024-01-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2182052, encodeId=b715218205245, content=偏重的研究方向：神经药物 经验分享：现在投稿后 with editor 时间会很久吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae325512706, createdName=ms3000002011952066, createdTime=Tue Jan 16 20:22:30 CST 2024, time=2024-01-16, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2183494, encodeId=13e621834949b, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：黏附分子;胃癌 经验分享：已经外审12周了，窒息了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11f06507596, createdName=ms9000001327347856, createdTime=Tue Jan 23 20:06:15 CST 2024, time=2024-01-23, status=1, ipAttribution=上海)]

2024-01-30 ms2000000381066259 来自江苏省

提交两个月，Under Review 了一个多月，也看到编辑邀请了9个审稿人，但都没有接受，上一次同行审稿时间是12月27日，到现在一直没有变化，发了邮件也没有收到回复，这是不想要但是一直拖着没有拒稿吗，救命一整个大焦虑，大家有这种情况吗

11 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2191663, encodeId=0ee92191663fa, content=有没有接收了的大佬，想问一下接收了多久之后会有DOI号呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10569161455, createdName=ms4000000526230130, createdTime=Thu Mar 07 09:43:33 CST 2024, time=2024-03-07, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2181913, encodeId=94cb2181913f9, content=偏重的研究方向：抗肿瘤药物 经验分享：投稿一个月，状态一直是with editor？还是同一个editor，之前拒稿让修改后重投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fb55313293, createdName=hongzhongshi, createdTime=Tue Jan 16 07:14:44 CST 2024, time=2024-01-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2181993, encodeId=a44d21819936e, content=投稿后第四天变成了DIP，目前一周多了，发邮件给编辑也没反应，要拒也给我个准信呀。科研人时间上的无奈呀。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06d55411127, createdName=ms5000001598335110, createdTime=Tue Jan 16 15:58:49 CST 2024, time=2024-01-16, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2185972, encodeId=3dba21859e250, content=投稿界面显示：Biochemical Pharmacology is currently receiving a high number of submissions. Handling time for your manuscript may be longer than usual.确实速度慢了好多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13159126824, createdName=ms7000001842576921, createdTime=Mon Feb 05 11:22:48 CST 2024, time=2024-02-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2184772, encodeId=564b2184e7214, content=提交两个月，Under Review 了一个多月，也看到编辑邀请了9个审稿人，但都没有接受，上一次同行审稿时间是12月27日，到现在一直没有变化，发了邮件也没有收到回复，这是不想要但是一直拖着没有拒稿吗，救命一整个大焦虑，大家有这种情况吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bcf6449852, createdName=ms2000000381066259, createdTime=Tue Jan 30 09:59:08 CST 2024, time=2024-01-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2184596, encodeId=77ad218459636, content=偏重的研究方向：肿瘤;中药 经验分享：想问一下大家最近的速度快吗？两周了都还是with editor。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9c98851241, createdName=ms9000000665899893, createdTime=Mon Jan 29 10:58:34 CST 2024, time=2024-01-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2184176, encodeId=ff5421841e6a8, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肝脏药理 经验分享：1.16晚上投稿，submiteed一周，1.23with editor，1.26under review，感觉最近进度是有点慢的，不如官网宣传的3天，共大家参考。前期投稿分享：一投的pharmcological research，当天桌拒，建议转投biomedicine&pharmcptherapy，这个杂志之前预警过（不太理解），没投了。二投的中国药理学报（APS），当天桌拒，然后投了这个杂志，希望顺利吧！也祝大家的paper能顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e446571671, createdName=ms4000000706495698, createdTime=Fri Jan 26 22:32:25 CST 2024, time=2024-01-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2184603, encodeId=582f218460333, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：抗肿瘤药物;肿瘤药理 经验分享：想问一下最近大家进展快吗？两周了还在with editor , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10569161455, createdName=ms4000000526230130, createdTime=Mon Jan 29 11:06:59 CST 2024, time=2024-01-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2182052, encodeId=b715218205245, content=偏重的研究方向：神经药物 经验分享：现在投稿后 with editor 时间会很久吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae325512706, createdName=ms3000002011952066, createdTime=Tue Jan 16 20:22:30 CST 2024, time=2024-01-16, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2183494, encodeId=13e621834949b, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：黏附分子;胃癌 经验分享：已经外审12周了，窒息了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11f06507596, createdName=ms9000001327347856, createdTime=Tue Jan 23 20:06:15 CST 2024, time=2024-01-23, status=1, ipAttribution=上海)]

2024-01-29 ms9000000665899893 来自重庆

偏重的研究方向：肿瘤;中药
经验分享：想问一下大家最近的速度快吗？两周了都还是with editor。

20 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2191663, encodeId=0ee92191663fa, content=有没有接收了的大佬，想问一下接收了多久之后会有DOI号呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10569161455, createdName=ms4000000526230130, createdTime=Thu Mar 07 09:43:33 CST 2024, time=2024-03-07, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2181913, encodeId=94cb2181913f9, content=偏重的研究方向：抗肿瘤药物 经验分享：投稿一个月，状态一直是with editor？还是同一个editor，之前拒稿让修改后重投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fb55313293, createdName=hongzhongshi, createdTime=Tue Jan 16 07:14:44 CST 2024, time=2024-01-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2181993, encodeId=a44d21819936e, content=投稿后第四天变成了DIP，目前一周多了，发邮件给编辑也没反应，要拒也给我个准信呀。科研人时间上的无奈呀。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06d55411127, createdName=ms5000001598335110, createdTime=Tue Jan 16 15:58:49 CST 2024, time=2024-01-16, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2185972, encodeId=3dba21859e250, content=投稿界面显示：Biochemical Pharmacology is currently receiving a high number of submissions. Handling time for your manuscript may be longer than usual.确实速度慢了好多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13159126824, createdName=ms7000001842576921, createdTime=Mon Feb 05 11:22:48 CST 2024, time=2024-02-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2184772, encodeId=564b2184e7214, content=提交两个月，Under Review 了一个多月，也看到编辑邀请了9个审稿人，但都没有接受，上一次同行审稿时间是12月27日，到现在一直没有变化，发了邮件也没有收到回复，这是不想要但是一直拖着没有拒稿吗，救命一整个大焦虑，大家有这种情况吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bcf6449852, createdName=ms2000000381066259, createdTime=Tue Jan 30 09:59:08 CST 2024, time=2024-01-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2184596, encodeId=77ad218459636, content=偏重的研究方向：肿瘤;中药 经验分享：想问一下大家最近的速度快吗？两周了都还是with editor。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9c98851241, createdName=ms9000000665899893, createdTime=Mon Jan 29 10:58:34 CST 2024, time=2024-01-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2184176, encodeId=ff5421841e6a8, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肝脏药理 经验分享：1.16晚上投稿，submiteed一周，1.23with editor，1.26under review，感觉最近进度是有点慢的，不如官网宣传的3天，共大家参考。前期投稿分享：一投的pharmcological research，当天桌拒，建议转投biomedicine&pharmcptherapy，这个杂志之前预警过（不太理解），没投了。二投的中国药理学报（APS），当天桌拒，然后投了这个杂志，希望顺利吧！也祝大家的paper能顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e446571671, createdName=ms4000000706495698, createdTime=Fri Jan 26 22:32:25 CST 2024, time=2024-01-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2184603, encodeId=582f218460333, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：抗肿瘤药物;肿瘤药理 经验分享：想问一下最近大家进展快吗？两周了还在with editor , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10569161455, createdName=ms4000000526230130, createdTime=Mon Jan 29 11:06:59 CST 2024, time=2024-01-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2182052, encodeId=b715218205245, content=偏重的研究方向：神经药物 经验分享：现在投稿后 with editor 时间会很久吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae325512706, createdName=ms3000002011952066, createdTime=Tue Jan 16 20:22:30 CST 2024, time=2024-01-16, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2183494, encodeId=13e621834949b, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：黏附分子;胃癌 经验分享：已经外审12周了，窒息了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11f06507596, createdName=ms9000001327347856, createdTime=Tue Jan 23 20:06:15 CST 2024, time=2024-01-23, status=1, ipAttribution=上海)]

2024-01-26 ms4000000706495698 来自上海

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：肝脏药理
经验分享：1.16晚上投稿，submiteed一周，1.23with editor，1.26under review，感觉最近进度是有点慢的，不如官网宣传的3天，共大家参考。前期投稿分享：一投的pharmcological research，当天桌拒，建议转投biomedicine&pharmcptherapy，这个杂志之前预警过（不太理解），没投了。二投的中国药理学报（APS），当天桌拒，然后投了这个杂志，希望顺利吧！也祝大家的paper能顺利。

14 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2191663, encodeId=0ee92191663fa, content=有没有接收了的大佬，想问一下接收了多久之后会有DOI号呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10569161455, createdName=ms4000000526230130, createdTime=Thu Mar 07 09:43:33 CST 2024, time=2024-03-07, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2181913, encodeId=94cb2181913f9, content=偏重的研究方向：抗肿瘤药物 经验分享：投稿一个月，状态一直是with editor？还是同一个editor，之前拒稿让修改后重投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fb55313293, createdName=hongzhongshi, createdTime=Tue Jan 16 07:14:44 CST 2024, time=2024-01-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2181993, encodeId=a44d21819936e, content=投稿后第四天变成了DIP，目前一周多了，发邮件给编辑也没反应，要拒也给我个准信呀。科研人时间上的无奈呀。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06d55411127, createdName=ms5000001598335110, createdTime=Tue Jan 16 15:58:49 CST 2024, time=2024-01-16, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2185972, encodeId=3dba21859e250, content=投稿界面显示：Biochemical Pharmacology is currently receiving a high number of submissions. Handling time for your manuscript may be longer than usual.确实速度慢了好多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13159126824, createdName=ms7000001842576921, createdTime=Mon Feb 05 11:22:48 CST 2024, time=2024-02-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2184772, encodeId=564b2184e7214, content=提交两个月，Under Review 了一个多月，也看到编辑邀请了9个审稿人，但都没有接受，上一次同行审稿时间是12月27日，到现在一直没有变化，发了邮件也没有收到回复，这是不想要但是一直拖着没有拒稿吗，救命一整个大焦虑，大家有这种情况吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bcf6449852, createdName=ms2000000381066259, createdTime=Tue Jan 30 09:59:08 CST 2024, time=2024-01-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2184596, encodeId=77ad218459636, content=偏重的研究方向：肿瘤;中药 经验分享：想问一下大家最近的速度快吗？两周了都还是with editor。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9c98851241, createdName=ms9000000665899893, createdTime=Mon Jan 29 10:58:34 CST 2024, time=2024-01-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2184176, encodeId=ff5421841e6a8, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肝脏药理 经验分享：1.16晚上投稿，submiteed一周，1.23with editor，1.26under review，感觉最近进度是有点慢的，不如官网宣传的3天，共大家参考。前期投稿分享：一投的pharmcological research，当天桌拒，建议转投biomedicine&pharmcptherapy，这个杂志之前预警过（不太理解），没投了。二投的中国药理学报（APS），当天桌拒，然后投了这个杂志，希望顺利吧！也祝大家的paper能顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e446571671, createdName=ms4000000706495698, createdTime=Fri Jan 26 22:32:25 CST 2024, time=2024-01-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2184603, encodeId=582f218460333, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：抗肿瘤药物;肿瘤药理 经验分享：想问一下最近大家进展快吗？两周了还在with editor , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10569161455, createdName=ms4000000526230130, createdTime=Mon Jan 29 11:06:59 CST 2024, time=2024-01-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2182052, encodeId=b715218205245, content=偏重的研究方向：神经药物 经验分享：现在投稿后 with editor 时间会很久吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae325512706, createdName=ms3000002011952066, createdTime=Tue Jan 16 20:22:30 CST 2024, time=2024-01-16, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2183494, encodeId=13e621834949b, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：黏附分子;胃癌 经验分享：已经外审12周了，窒息了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11f06507596, createdName=ms9000001327347856, createdTime=Tue Jan 23 20:06:15 CST 2024, time=2024-01-23, status=1, ipAttribution=上海)]

2024-01-29 ms4000000526230130 来自重庆

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：抗肿瘤药物;肿瘤药理
经验分享：想问一下最近大家进展快吗？两周了还在with editor

12 0

[GetPortalCommentsPageByObjectIdResponse(id=2191663, encodeId=0ee92191663fa, content=有没有接收了的大佬，想问一下接收了多久之后会有DOI号呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10569161455, createdName=ms4000000526230130, createdTime=Thu Mar 07 09:43:33 CST 2024, time=2024-03-07, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2181913, encodeId=94cb2181913f9, content=偏重的研究方向：抗肿瘤药物 经验分享：投稿一个月，状态一直是with editor？还是同一个editor，之前拒稿让修改后重投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fb55313293, createdName=hongzhongshi, createdTime=Tue Jan 16 07:14:44 CST 2024, time=2024-01-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2181993, encodeId=a44d21819936e, content=投稿后第四天变成了DIP，目前一周多了，发邮件给编辑也没反应，要拒也给我个准信呀。科研人时间上的无奈呀。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06d55411127, createdName=ms5000001598335110, createdTime=Tue Jan 16 15:58:49 CST 2024, time=2024-01-16, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2185972, encodeId=3dba21859e250, content=投稿界面显示：Biochemical Pharmacology is currently receiving a high number of submissions. Handling time for your manuscript may be longer than usual.确实速度慢了好多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13159126824, createdName=ms7000001842576921, createdTime=Mon Feb 05 11:22:48 CST 2024, time=2024-02-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2184772, encodeId=564b2184e7214, content=提交两个月，Under Review 了一个多月，也看到编辑邀请了9个审稿人，但都没有接受，上一次同行审稿时间是12月27日，到现在一直没有变化，发了邮件也没有收到回复，这是不想要但是一直拖着没有拒稿吗，救命一整个大焦虑，大家有这种情况吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bcf6449852, createdName=ms2000000381066259, createdTime=Tue Jan 30 09:59:08 CST 2024, time=2024-01-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2184596, encodeId=77ad218459636, content=偏重的研究方向：肿瘤;中药 经验分享：想问一下大家最近的速度快吗？两周了都还是with editor。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9c98851241, createdName=ms9000000665899893, createdTime=Mon Jan 29 10:58:34 CST 2024, time=2024-01-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2184176, encodeId=ff5421841e6a8, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肝脏药理 经验分享：1.16晚上投稿，submiteed一周，1.23with editor，1.26under review，感觉最近进度是有点慢的，不如官网宣传的3天，共大家参考。前期投稿分享：一投的pharmcological research，当天桌拒，建议转投biomedicine&pharmcptherapy，这个杂志之前预警过（不太理解），没投了。二投的中国药理学报（APS），当天桌拒，然后投了这个杂志，希望顺利吧！也祝大家的paper能顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e446571671, createdName=ms4000000706495698, createdTime=Fri Jan 26 22:32:25 CST 2024, time=2024-01-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2184603, encodeId=582f218460333, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：抗肿瘤药物;肿瘤药理 经验分享：想问一下最近大家进展快吗？两周了还在with editor , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10569161455, createdName=ms4000000526230130, createdTime=Mon Jan 29 11:06:59 CST 2024, time=2024-01-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2182052, encodeId=b715218205245, content=偏重的研究方向：神经药物 经验分享：现在投稿后 with editor 时间会很久吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae325512706, createdName=ms3000002011952066, createdTime=Tue Jan 16 20:22:30 CST 2024, time=2024-01-16, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2183494, encodeId=13e621834949b, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：黏附分子;胃癌 经验分享：已经外审12周了，窒息了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11f06507596, createdName=ms9000001327347856, createdTime=Tue Jan 23 20:06:15 CST 2024, time=2024-01-23, status=1, ipAttribution=上海)]

2024-01-16 ms3000002011952066 来自河南省

偏重的研究方向：神经药物
经验分享：现在投稿后 with editor 时间会很久吗？

11 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2191663, encodeId=0ee92191663fa, content=有没有接收了的大佬，想问一下接收了多久之后会有DOI号呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10569161455, createdName=ms4000000526230130, createdTime=Thu Mar 07 09:43:33 CST 2024, time=2024-03-07, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2181913, encodeId=94cb2181913f9, content=偏重的研究方向：抗肿瘤药物 经验分享：投稿一个月，状态一直是with editor？还是同一个editor，之前拒稿让修改后重投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fb55313293, createdName=hongzhongshi, createdTime=Tue Jan 16 07:14:44 CST 2024, time=2024-01-16, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2181993, encodeId=a44d21819936e, content=投稿后第四天变成了DIP，目前一周多了，发邮件给编辑也没反应，要拒也给我个准信呀。科研人时间上的无奈呀。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06d55411127, createdName=ms5000001598335110, createdTime=Tue Jan 16 15:58:49 CST 2024, time=2024-01-16, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2185972, encodeId=3dba21859e250, content=投稿界面显示：Biochemical Pharmacology is currently receiving a high number of submissions. Handling time for your manuscript may be longer than usual.确实速度慢了好多, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13159126824, createdName=ms7000001842576921, createdTime=Mon Feb 05 11:22:48 CST 2024, time=2024-02-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2184772, encodeId=564b2184e7214, content=提交两个月，Under Review 了一个多月，也看到编辑邀请了9个审稿人，但都没有接受，上一次同行审稿时间是12月27日，到现在一直没有变化，发了邮件也没有收到回复，这是不想要但是一直拖着没有拒稿吗，救命一整个大焦虑，大家有这种情况吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bcf6449852, createdName=ms2000000381066259, createdTime=Tue Jan 30 09:59:08 CST 2024, time=2024-01-30, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2184596, encodeId=77ad218459636, content=偏重的研究方向：肿瘤;中药 经验分享：想问一下大家最近的速度快吗？两周了都还是with editor。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9c98851241, createdName=ms9000000665899893, createdTime=Mon Jan 29 10:58:34 CST 2024, time=2024-01-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2184176, encodeId=ff5421841e6a8, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肝脏药理 经验分享：1.16晚上投稿，submiteed一周，1.23with editor，1.26under review，感觉最近进度是有点慢的，不如官网宣传的3天，共大家参考。前期投稿分享：一投的pharmcological research，当天桌拒，建议转投biomedicine&pharmcptherapy，这个杂志之前预警过（不太理解），没投了。二投的中国药理学报（APS），当天桌拒，然后投了这个杂志，希望顺利吧！也祝大家的paper能顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e446571671, createdName=ms4000000706495698, createdTime=Fri Jan 26 22:32:25 CST 2024, time=2024-01-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2184603, encodeId=582f218460333, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：抗肿瘤药物;肿瘤药理 经验分享：想问一下最近大家进展快吗？两周了还在with editor , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10569161455, createdName=ms4000000526230130, createdTime=Mon Jan 29 11:06:59 CST 2024, time=2024-01-29, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2182052, encodeId=b715218205245, content=偏重的研究方向：神经药物 经验分享：现在投稿后 with editor 时间会很久吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ae325512706, createdName=ms3000002011952066, createdTime=Tue Jan 16 20:22:30 CST 2024, time=2024-01-16, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2183494, encodeId=13e621834949b, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：黏附分子;胃癌 经验分享：已经外审12周了，窒息了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11f06507596, createdName=ms9000001327347856, createdTime=Tue Jan 23 20:06:15 CST 2024, time=2024-01-23, status=1, ipAttribution=上海)]

2024-01-23 ms9000001327347856 来自上海

审稿速度:6.0 | 投稿命中率:25.0
偏重的研究方向：黏附分子;胃癌
经验分享：已经外审12周了，窒息了

186 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务